BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23900743)

  • 21. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
    Pant A; Lee II; Lu Z; Rueda BR; Schink J; Kim JJ
    PLoS One; 2012; 7(7):e41593. PubMed ID: 22911820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
    Kumarasamy VM; Sun D
    Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
    Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
    Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
    Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
    J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antineoplastic Activity of an Old Natural Antidiabetic Biguanide on the Human Thyroid Carcinoma Cell Line.
    Nozhat Z; Zarkesh M; Baldini E; Mohammadi-Yeganeh S; Azizi F; Hedayati M
    Anticancer Agents Med Chem; 2022; 22(4):713-720. PubMed ID: 33461474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells.
    Du ZX; Zhang HY; Gao DX; Wang HQ; Li YJ; Liu GL
    Exp Mol Med; 2006 Jun; 38(3):230-40. PubMed ID: 16819281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.
    Drosten M; Stiewe T; Pützer BM
    Hum Gene Ther; 2003 Jul; 14(10):971-82. PubMed ID: 12869215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT.
    Baldini E; Arlot-Bonnemains Y; Sorrenti S; Mian C; Pelizzo MR; De Antoni E; Palermo S; Morrone S; Barollo S; Nesca A; Moretti CG; D'Armiento M; Ulisse S
    BMC Cancer; 2011 Sep; 11():411. PubMed ID: 21943074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways.
    Mazumdar M; Adhikary A; Chakraborty S; Mukherjee S; Manna A; Saha S; Mohanty S; Dutta A; Bhattacharjee P; Ray P; Chattopadhyay S; Banerjee S; Chakraborty J; Ray AK; Sa G; Das T
    Apoptosis; 2013 May; 18(5):589-604. PubMed ID: 23329180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta.
    Adler JT; Cook M; Luo Y; Pitt SC; Ju J; Li W; Shen B; Kunnimalaiyaan M; Chen H
    Mol Cancer Ther; 2009 Apr; 8(4):914-20. PubMed ID: 19372564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.
    Strock CJ; Park JI; Rosen M; Dionne C; Ruggeri B; Jones-Bolin S; Denmeade SR; Ball DW; Nelkin BD
    Cancer Res; 2003 Sep; 63(17):5559-63. PubMed ID: 14500395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
    Starenki D; Hong SK; Lloyd RV; Park JI
    Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates.
    Morisi R; Celano M; Tosi E; Schenone S; Navarra M; Ferretti E; Costante G; Durante C; Botta G; D'Agostino M; Brullo C; Filetti S; Botta M; Russo D
    J Endocrinol Invest; 2007 Nov; 30(10):RC31-4. PubMed ID: 18075281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors.
    Cohen MS; Hussain HB; Moley JF
    Surgery; 2002 Dec; 132(6):960-6; discussion 966-7. PubMed ID: 12490842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation.
    Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E
    Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.
    Broutin S; Ameur N; Lacroix L; Robert T; Petit B; Oumata N; Talbot M; Caillou B; Schlumberger M; Dupuy C; Bidart JM
    Clin Cancer Res; 2011 Apr; 17(7):2044-54. PubMed ID: 21325074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiproliferative effects of Src inhibition on medullary thyroid cancer.
    Liu Z; Falola J; Zhu X; Gu Y; Kim LT; Sarosi GA; Anthony T; Nwariaku FE
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3503-9. PubMed ID: 15240638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation.
    Ludwig L; Kessler H; Wagner M; Hoang-Vu C; Dralle H; Adler G; Böhm BO; Schmid RM
    Cancer Res; 2001 Jun; 61(11):4526-35. PubMed ID: 11389085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on ret proto-oncogene activity.
    Zhu W; Hai T; Ye L; Cote GJ
    J Clin Endocrinol Metab; 2010 Jan; 95(1):439-44. PubMed ID: 19897677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer.
    Agarwal E; Chaudhuri A; Leiphrakpam PD; Haferbier KL; Brattain MG; Chowdhury S
    BMC Cancer; 2014 Mar; 14():145. PubMed ID: 24581231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.